The P450 system and CV outcomes with clopidogrel

December 2010
Internal Medicine Alert;12/15/2010, Vol. 32 Issue 23, p183
The article reports on the findings of a study concerning the use of CYP2C19 genotyping to determine the efficacy of clopidogrel treatment for persons with atrial fibrillation in the U.S.


Related Articles

  • Clopidogrel + aspirin in atrial fibrillation.  // Neurology Alert;Aug2009 Clinical Briefs in, Vol. 14 Issue 8, p15 

    The article discusses the effect of clopidogrel (CPG) when combined with aspirin (ASA) in the treatment of patients with atrial fibrillation (FIB). It references a study by The ACTIVE Investigators, published in the 2009 issue of "N Engl J Med." Some FIB patients with indications for coumadin...

  • Clopidogrel + aspirin in atrial fibrillation. Kuritzky, Louis // Clinical Cardiology Alert;Aug2009 Clinical Briefs in, Vol. 14 Issue 8, p15 

    The article discusses research on the clinical use of clopidogrel and aspirin in atrial fibrillation. It references the study "The ACTIVE Investigators. Effect of Clopidogrel Added to Aspirin in Patients With Atrial Fibrillation," published in the 2009 issue of the "New England Journal of...

  • In patients with atrial fibrillation, adding clopidogrel to aspirin reduced major vascular events but increased bleeding. Cairns, John A; Connolly, S. J. // ACP Journal Club;9/22/2009, Vol. 151 Issue 3, p6 

    The article presents the findings of a study to assess whether adding clopidogrel to aspirin reduces risk for vascular events in patients with atrial fibrillation (AF) who are unsuitable for vitamin K antagonist therapy. The research method included randomized placebo controlled trials. The...

  • Risk of VTE recurrence higher for patients with nonsurgical risk factors. Garrett, Anna D. // Drug Topics;May2011, Vol. 155 Issue 5, p43 

    The article highlights several studies related to medicine. One study reveals that a patient with first episode of symptomatic venous thromboembolism (VTE) provoked by a transient risk factor (TRF) usually receives anticoagulation for three months. Another study found that oral direct factor Xa...

  • Novel oral anticoagulants: too good to be true? Schachter, Michael // Postgraduate Medical Journal;Sep2014, Vol. 90 Issue 1067, p485 

    The author reflects on the pharmacological benefits of the novel oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban for treatment of cardiovascular disease. He wonders if the development of antiplatelet drugs in acute coronary syndromes will have preventive efficacy...

  • CARDIOVASCULAR. Cottrell, Neil // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 2, p152 

    The article presents abstracts on cardiovascular topics such as the use of prasugrel or clopidogrel for ST segment elevation myocardial infaction (STEMI), the use of valsartan for atrial fibrillation (AF), and the use of clopidogrel with aspirin for AF.

  • Akutni infarkt miokarda kao posljedica embolizacije u fibrilaciji atrija -- prikaz slučaja. Vujeva, Božo; Hadžibegović, Irzal; Prvulović, Đeiti; Gabaldo, Krešimir // Cardiologia Croatica;Sep/Oct2014, Vol. 9 Issue 9/10, p350 

    INTRODUCTION: Atrial fibrillation is one of the most common arrhythmias and carries a great risk for cardioembolisation, with stroke and acute limb or mesenteric ischemia as one of the most severe consequences. Myocardial infarction is not commonly reported thromboembolic complication of atrial...

  • Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor. Serebruany, Victor L. // Cardiology;Jan2011, Vol. 117 Issue 3, p231 

    The striking success of ticagrelor in PLATO when compared with recent important but far less impressive antiplatelet trials suggests the fundamental difference of ticagrelor from thienopyridines, such as ticlopidone, clopidogrel, and prasugrel. In fact, being a P2Y12 platelet receptor inhibitor,...

  • Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Suh, Soon; Kang, Woong; Oh, Pyung; Choi, Hanul; Moon, Chan; Lee, Kyounghoon; Han, Seung; Ahn, Taehoon; Choi, In; Shin, Eak // Heart & Vessels;Sep2014, Vol. 29 Issue 5, p578 

    There are limited data on the optimal antithrombotic therapy for patients with atrial fibrillation (AF) who undergoing coronary stenting. We reviewed 203 patients (62.6 % men, mean age 68.3 ± 10.1 years) between 2003 and 2012, and recorded clinical and demographic characteristics of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics